ORMP stock icon

Oramed Pharmaceuticals

2.51 USD
-0.01
0.40%
At close Dec 5, 4:00 PM EST
1 day
-0.40%
5 days
5.91%
1 month
6.81%
3 months
8.66%
6 months
13.57%
Year to date
2.45%
1 year
18.40%
5 years
-46.25%
10 years
-57.89%
 

About: Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.

Employees: 15

0
Funds holding %
of 6,790 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

320% more call options, than puts

Call options by funds: $21K | Put options by funds: $5K

10% more capital invested

Capital invested by funds: $15.4M [Q2] → $17M (+$1.58M) [Q3]

2.35% more ownership

Funds ownership: 14.72% [Q2] → 17.07% (+2.35%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 14

8% less funds holding

Funds holding: 59 [Q2] → 54 (-5) [Q3]

38% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 13

Research analyst outlook

We haven’t received any recent analyst ratings for ORMP.

Financial journalist opinion

Neutral
PRNewsWire
1 month ago
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
NEW YORK , Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the execution of definitive agreements for the restructuring of a portion of its existing Senior Secured Promissory Note from Scilex Holding Company (Nasdaq: SCLX) ("Scilex"), a company focused on non-opioid pain management products. Key Highlights: Oramed, affiliates of Murchinson and 3i LP, entered into definitive agreements with Scilex for the purchase and sale of new tranche B senior secured convertible notes ("Notes") in the aggregate principal amount of $50 million (the "New Financing") and warrants to purchase up to 7,500,000 shares of the Company's common stock in the aggregate in a registered direct offering.
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
Neutral
InvestorPlace
4 months ago
3 Micro-Cap Moonshots for Fearless Investors
When discussing micro-cap stocks, it's important to recognize their general overlap with the world of penny stocks. These stocks trade as shares of companies with market capitalizations between $50 million and $300 million.
3 Micro-Cap Moonshots for Fearless Investors
Neutral
PRNewsWire
5 months ago
Oramed Letter to Shareholders
Stock Repurchase Program Scilex Senior Secured Note Phase 3 Oral Insulin Trial in US JV with Chinese Partner, HTIT NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP)  ("Oramed") ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. Dear Shareholders, In light of our recent announcement regarding Oramed's $20 million stock repurchase program, we believe this is an opportune moment to provide our shareholders with a comprehensive update on our activities and progress.
Oramed Letter to Shareholders
Neutral
PRNewsWire
5 months ago
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
NEW YORK , June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months (the "Stock Buy Back Program").     The manner, timing and number of shares purchased will be at the Company's discretion, depending on a number of factors, including price, general business and market conditions, and alternative investment opportunities.
Oramed Pharmaceuticals Inc. Announces the Buy-Back of its Common Stock
Neutral
PRNewsWire
9 months ago
Oramed Letter to Shareholders
Initiating Phase 3 oral insulin trial in the United States under a new protocol  JV with Chinese Partner, HTIT Scilex Senior Secured Note PeriTech Asset Purchase & Strategic Out-licensing  NEW YORK , Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron. Dear Shareholders, I am pleased to share with you an update regarding Oramed.
Oramed Letter to Shareholders
Charts implemented using Lightweight Charts™